Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-116597
  • Myocardial infarction (MI) induces a complex inflammatory immune response, followed by the remodelling of the heart muscle and scar formation. The rapid regeneration of the blood vessel network system by the attraction of hematopoietic stem cells is beneficial for heart function. Despite the important role of chemokines in these processes, their use in clinical practice has so far been limited by their limited availability over a long time-span in vivo. Here, a method is presented to increase physiological availability of chemokines at the siteMyocardial infarction (MI) induces a complex inflammatory immune response, followed by the remodelling of the heart muscle and scar formation. The rapid regeneration of the blood vessel network system by the attraction of hematopoietic stem cells is beneficial for heart function. Despite the important role of chemokines in these processes, their use in clinical practice has so far been limited by their limited availability over a long time-span in vivo. Here, a method is presented to increase physiological availability of chemokines at the site of injury over a defined time-span and simultaneously control their release using biodegradable hydrogels. Two different biodegradable hydrogels were implemented, a fast degradable hydrogel (FDH) for delivering Met-CCL5 over 24hrs and a slow degradable hydrogel (SDH) for a gradual release of protease-resistant CXCL12 (S4V) over 4weeks. We demonstrate that the time-controlled release using Met-CCL5-FDH and CXCL12 (S4V)-SDH suppressed initial neutrophil infiltration, promoted neovascularization and reduced apoptosis in the infarcted myocardium. Thus, we were able to significantly preserve the cardiac function after MI. This study demonstrates that time-controlled, biopolymer-mediated delivery of chemokines represents a novel and feasible strategy to support the endogenous reparatory mechanisms after MI and may compliment cell-based therapies.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Delia Projahn, Sakine Simsekyilmaz, Smriti Singh, Isabella Kanzler, Birgit K. Kramp, Marcella Langer, Alexandrina Burlacu, Jürgen Bernhagen, Doris Klee, Alma Zernecke, Tilman M. Hackeng, Jürgen Groll, Christian Weber, Elisa A. Liehn, Roy R. Koenen
URN:urn:nbn:de:bvb:20-opus-116597
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):Journal of Cellular and Molecular Medicine
ISSN:1582-4934
Erscheinungsjahr:2014
Band / Jahrgang:18
Heft / Ausgabe:5
Seitenangabe:790-800
Originalveröffentlichung / Quelle:Journal of Cellular and Molecular Medicine Vol 18, No 5, 2014 pp. 790-800. doi:10.1111/jcmm.12225
DOI:https://doi.org/10.1111/jcmm.12225
PubMed-ID:https://pubmed.ncbi.nlm.nih.gov/24512349
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):cardiovascular pharmacology; chemokines; endothelial progenitor cells; factor-I; heart-failure; left-ventricular function; rat model; recruitment; remodelling; therapy
Datum der Freischaltung:03.08.2015
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung